Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Fineline Cube Jun 24, 2026
Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Company Deals

BioArctic Partners with Eli Lilly on Novel Neurodegenerative Disease Therapy Using BrainTransporter Platform

Fineline Cube Jun 23, 2026
Policy / Regulatory

China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted

Fineline Cube Jun 24, 2026
Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Fineline Cube Jun 25, 2026
Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Fineline Cube Jun 25, 2026
Company Drug

CStone Pharmaceuticals Doses First Patient in CS2009 Phase I Study for Solid Tumors

Fineline Cube Mar 4, 2025

China-based CStone Pharmaceuticals (HKG: 2616) announced the first patient dosing in a global, multi-center Phase...

Company Deals

AbbVie Enters Obesity Field with Gubra’s GUB014295 Licensing Deal

Fineline Cube Mar 3, 2025

US pharmaceutical giant AbbVie (NYSE: ABBV) announced that it is making significant progress in the...

Company Medical Device

Zeiss Group’s VISUMAX 800 with SMILE pro Software Approved by China’s NMPA

Fineline Cube Mar 3, 2025

Germany-based Zeiss Group, a specialist in optical systems and optoelectronic product manufacturing, announced that it...

Company Drug

Laekna’s LAE120 Receives FDA Approval for Solid Tumor Clinical Trials

Fineline Cube Mar 3, 2025

Sino-US biotech company Laekna, Inc. (HKG: 2105) announced that it has received clinical trial approval...

Company Drug

SynerK’s SNK-2726 Gets FDA Green Light for Phase I Hypertension Study

Fineline Cube Mar 3, 2025

SynerK, an RNA-targeted therapy developer with operations in Boston, US, and Beijing and Suzhou, China,...

Company Deals

Omron Healthcare and China Jo-Jo Drugstores Launch Atrial Fibrillation Screening Zone

Fineline Cube Mar 3, 2025

A joint effort between Japan-based Omron Healthcare and China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD), a...

Company Deals

WORK Medical and Chartwell Med Partner on Investment Tools for Healthcare Projects

Fineline Cube Mar 3, 2025

WORK Medical Technology Group Ltd (NASDAQ: WOK), a medical consumables company based in Hangzhou, has...

Company Drug

Innovent Biologics Doses First Patient in IBI363 Melanoma Study vs Keytruda

Fineline Cube Mar 3, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the pivotal regulatory...

Deals Drug

Eyebright Medtech Plans Private Placement to Expand Contact Lens Production

Fineline Cube Mar 3, 2025

China-based Eyebright Medical Technology (Beijing) Co., Ltd. (SHA: 688050), an ophthalmic medical device manufacturer, announced...

Company Drug

Sinocelltech’s Finotonlimab Gets NMPA Approval for Liver Cancer Treatment

Fineline Cube Mar 3, 2025

China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received another indication approval from...

Company Deals

Danatlas Raises RMB 150M to Advance Synthetic Lethality Drug Pipeline

Fineline Cube Mar 3, 2025

Beijing-headquartered Danatlas, a first-in-class drug developer in the synthetic lethality field, has reportedly raised RMB...

Company Deals

Magnet Biomedicine and Eli Lilly Partner on Molecular Glue Therapeutics

Fineline Cube Mar 3, 2025

US-based molecular glue specialist Magnet Biomedicine has entered into a collaboration and license agreement with...

Company Drug

AstraZeneca and Amgen’s Tezspire Shows Positive Results in Phase III Study

Fineline Cube Mar 3, 2025

AstraZeneca (NASDAQ: AZN) and Amgen (NASDAQ: AMGN) have jointly announced positive results from the Phase...

Company Deals Digital

Baidu Health Partners with Jolly Pharma to Boost Digital Drug Marketing

Fineline Cube Mar 3, 2025

Baidu Health, an internet giant, has entered into a partnership with Zhejiang Jolly Pharmaceutical Co.,...

Company Deals

Duality Biotherapeutics Updates IPO Filing with HKSE under Chapter 18A Rules

Fineline Cube Mar 3, 2025

China-based Duality Biotherapeutics, Inc. updated its initial public offering (IPO) filing to the Hong Kong...

Company Drug

CARsgen’s CT041 Awarded Breakthrough Therapy Designation for Gastric Cancer

Fineline Cube Mar 3, 2025

CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that its chimeric antigen receptor (CAR) T-cell therapy,...

Company Deals

Huge Dental Files for Hong Kong IPO with Diverse Dental Product Portfolio

Fineline Cube Mar 3, 2025

Shandong-based dental materials company Huge Dental Limited has made an initial public offering (IPO) filing...

Drug

CSPC Pharmaceutical’s Sirolimus Receives BTD for Malignant PEComa Treatment

Fineline Cube Mar 3, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received Breakthrough Therapy Designation...

Company Deals

Pulnovo Medical Raises USD 100M in Series C Financing for Global Expansion

Fineline Cube Mar 3, 2025

Wuxi-based Pulnovo Medical Limited, a developer of medical devices for pulmonary hypertension and heart failure,...

Company Deals

Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs

Fineline Cube Mar 3, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the sale of 4,947,181 shares in...

Posts pagination

1 … 225 226 227 … 688

Recent updates

  • Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline
  • Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster
  • Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP
  • Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients
  • Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Company Drug

Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.